10-Q: Trailblazer Merger I Reports Q3 Loss, Extends Cyabra Deal Deadline

Trailblazer Merger Corporation I reported a significant net loss in Q3 2025, extended its business combination deadline with Cyabra, and addressed liquidity concerns.

Summary

• Reported a net loss of $3,693,011 for the three months ended September 30, 2025, and $4,384,093 for the nine months ended September 30, 2025.
• The net loss for the nine months ended September 30, 2025, contrasts sharply with a net income of $735,207 for the same period in 2024.
• Operating and formation costs increased to $1,675,074 for the nine months ended September 30, 2025, from $1,493,646 in 2024.
• Interest earned on marketable securities in the Trust Account significantly decreased to $851,602 for the nine months ended September 30, 2025, from $2,814,405 in 2024.
• Incurred a $6,222,973 loss on debt extinguishment of a promissory note and recognized a $2,856,375 gain on change in fair value of the promissory note during the nine months ended September 30, 2025.
• Cash balance decreased to $19,183 as of September 30, 2025, from $63,829 at December 31, 2024.
• Total liabilities surged to $36,123,855 as of September 30, 2025, from $7,181,089 at December 31, 2024, primarily due to the promissory note and stockholders redemption payable.
• Stockholders Deficit worsened to $(11,867,637) as of September 30, 2025, from $(6,081,287) at December 31, 2024.
• The business combination deadline with Cyabra Strategy Ltd. was extended from September 30, 2025, to March 30, 2026, through monthly extensions.
• The Sponsor deposited $11,649 on October 10, 2025, and another $11,649 on November 4, 2025, into the Trust Account for extensions.
• 2,046,800 shares were tendered for redemption on September 29, 2025, with $23,950,427 withdrawn on October 22, 2025, to pay redeeming holders at approximately $11.70 per share.
• The merger agreement with Cyabra was amended on November 6, 2025, increasing the Base Purchase Price from $70,000,000 to $106,000,000 and changing the PIPE Investment structure.

Sentiment

Score: 2

Explanation: The company faces significant financial challenges, including a substantial net loss, critically low cash, and a worsening stockholders' deficit. The repeated extensions of the business combination deadline, high shareholder redemptions, and identified material weaknesses in internal controls indicate considerable operational and financial risk. While the increase in the target's purchase price and waiver of some fees are minor positives, they are overshadowed by the going concern uncertainty and the overall negative financial performance.

Positives

• Stockholders approved the extension of the business combination deadline until March 30, 2026, providing more time to complete the merger with Cyabra.
• The Base Purchase Price for the Cyabra merger was increased from $70,000,000 to $106,000,000, potentially indicating a higher valuation for the target company.
• LifeSci Capital LLC waived its advisory fee from Trailblazer, reducing a potential financial obligation for the SPAC.
• Recognized a gain on change in fair value of promissory note of $2,856,375 for the nine months ended September 30, 2025.

Negatives

• Reported a significant net loss of $4,384,093 for the nine months ended September 30, 2025, a substantial decline from a net income of $735,207 in the prior year period.
• Interest earned on marketable securities held in the Trust Account decreased significantly to $851,602 for the nine months ended September 30, 2025, from $2,814,405 in 2024, impacting non-operating income.
• Incurred a substantial loss on debt extinguishment of a promissory note amounting to $6,222,973 during the nine months ended September 30, 2025.
• Cash balance in the operating account is critically low at $19,183 as of September 30, 2025, down from $63,829 at December 31, 2024.
• Total liabilities increased dramatically to $36,123,855 as of September 30, 2025, from $7,181,089 at December 31, 2024.
• Stockholders Deficit worsened to $(11,867,637) as of September 30, 2025, from $(6,081,287) at December 31, 2024.
• A large number of shares (2,046,800) were tendered for redemption on September 29, 2025, indicating significant shareholder dissent or lack of confidence.
• Identified a material weakness in internal controls related to the valuation of complex financial instruments associated with the promissory note.
• Management expressed substantial doubt about the company's ability to continue as a going concern for one year from the date the financial statements are issued.

Risks

• **Going Concern Uncertainty**: The company currently lacks the liquidity to sustain operations for a reasonable period and faces mandatory liquidation if the Business Combination with Cyabra is not consummated by March 30, 2026 (if fully extended).
• **Business Combination Failure**: There is no assurance that the company will be able to complete the Business Combination successfully, which would lead to liquidation.
• **Shareholder Redemptions**: High redemption rates of Class A common stock reduce the funds available in the Trust Account, potentially impacting the ability to meet the minimum cash condition for the Business Combination or requiring a reduction in the PIPE Investment.
• **Dilution from Equity Issuances**: Issuance of additional shares in connection with the Business Combination may significantly dilute existing equity interests and could cause a change in control.
• **Debt Burden**: Incurring significant debt could lead to default, acceleration of obligations, inability to obtain additional financing, and reduced funds for operations or dividends.
• **Excise Tax**: Redemptions or repurchases after December 31, 2022, may be subject to a new U.S. federal 1% excise tax, which could reduce cash available for the Business Combination.
• **Internal Control Weaknesses**: Identified material weaknesses in disclosure controls and procedures related to the valuation of complex financial instruments, which could affect financial reporting accuracy.
• **Dependence on Sponsor Funding**: The company relies on the Sponsor or affiliates for loans to fund working capital deficiencies or transaction costs, and there is no obligation for them to provide such funds.
• **Market Price Volatility**: The prevailing market prices for common stock, rights, and/or warrants may be adversely affected by various factors, including the issuance of additional shares or debt.

Future Outlook

The company intends to complete its Business Combination with Cyabra Strategy Ltd. before the mandatory liquidation date of March 30, 2026 (if fully extended). The post-Business Combination entity, Cyabra, Inc., is expected to list on The Nasdaq Stock Market, LLC. The merger agreement has been amended to increase the Base Purchase Price and adjust the PIPE investment structure, with earnout shares tied to future stock price performance. However, management has identified substantial doubt about the company's ability to continue as a going concern due to liquidity issues and the uncertainty of completing the Business Combination.

Management Comments

• "Management has determined that the Company currently lacks the liquidity it needs to sustain operations for a reasonable period of time, which is considered to be at least one year from the date that the consolidated financial statements are issued as it expects to continue to incur significant costs in pursuit of its acquisition plans."
• "Management has determined that mandatory liquidation, should a Business Combination not occur, and potential subsequent dissolution and the liquidity issue raise substantial doubt about the Companys ability to continue as a going concern for one year from the date the consolidated financial statements are issued."
• "We intend to complete a Business Combination with Cyabra (see Note 6) before the mandatory liquidation date."
• "We believe our efforts will enhance our controls relating to accounting for complex financial transactions, but we can offer no assurance that our controls will not require additional review and modification in the future as industry accounting practice may evolve over time."

Industry Context

This filing reflects the ongoing challenges faced by Special Purpose Acquisition Companies (SPACs) in completing business combinations within their mandated timelines. The repeated extensions, significant shareholder redemptions, and the need for sponsor funding highlight the difficult market conditions for de-SPAC transactions. The shift in the PIPE investment structure and the increase in the target's valuation could indicate adjustments to market realities or a re-evaluation of Cyabra's potential, but also underscore the complexities and negotiations involved in these deals. The high redemption rate is a common trend in the SPAC market, often leading to reduced trust account sizes for the target company.

Comparison to Industry Standards

• The high redemption rate of 2,046,800 shares (out of 2,452,315 Class A shares outstanding as of November 17, 2025, before this redemption) is indicative of a broader trend in the SPAC market where public shareholders often redeem their shares rather than participate in the de-SPAC transaction, especially in volatile market conditions or when the target company's valuation or prospects are perceived as uncertain. This is comparable to other SPACs that have faced significant redemptions, such as Digital World Acquisition Corp. (DWAC) or Gores Guggenheim (GGPI), which saw substantial redemptions prior to their respective business combinations.
• The repeated extensions of the business combination deadline, funded by the sponsor, are a common practice among SPACs struggling to close deals, similar to many SPACs in 2023-2025 that have sought multiple extensions to avoid liquidation.
• The identified material weakness in internal controls related to complex financial instruments is a concern, though not unique to this SPAC. Many smaller public companies, including SPACs, face challenges in accounting for complex financial instruments like warrants and convertible notes, as seen in various SEC comment letters and restatements across the SPAC industry.

Corporate Governance

Related Party Transactions

• **Promissory Notes from Sponsor**: The Sponsor provided non-interest bearing unsecured promissory notes to the company, which were repeatedly amended and increased in maximum amount, reaching $4,030,000 by May 29, 2025.
• **Second Amended and Restated Promissory Note**: On July 29, 2025, the original promissory note was extinguished and replaced by a new note from the Sponsor, with the outstanding principal balance converting into preferred stock (stated value 200% of principal) upon Business Combination closing. This note was further increased by $300,000 to $4,330,000 on September 30, 2025.
• **Extension Payments**: The Sponsor deposited a total of $2,379,439 into the Trust Account to extend the business combination deadline through September 30, 2025, and subsequently deposited $11,649 on October 10, 2025, and $11,649 on November 4, 2025, for further monthly extensions.
• **Alpha Capital Anstalt Loans to Cyabra**: Alpha Capital Anstalt, an affiliate of the Sponsor, provided Cyabra with a $3.4 million loan in 2024 (2024 Convertible Notes) and a $1.0 million loan in 2025 (2025 Note).
• **Sponsor Waiver of Redemption Rights**: The Sponsor agreed to waive its redemption rights with respect to its Founder Shares and Public Shares held in connection with the completion of a Business Combination and its liquidation rights with respect to Founder Shares if the company fails to complete a Business Combination.
• **Sponsor Indemnification**: The Sponsor agreed to be liable to the company if third-party claims reduce funds in the Trust Account below certain thresholds, subject to waivers.
• **Working Capital Loans**: The Sponsor or its affiliates, officers, and directors may loan the company funds for working capital, with up to $1,500,000 convertible into units of the post-Business Combination entity.

Stakeholder Impact

• **Shareholders**: Existing public shareholders face significant dilution risk from potential equity issuances and the conversion of the Sponsor's promissory note into preferred stock. Those who redeemed their shares received cash, but the high redemption rate indicates a loss of confidence or opportunity cost. Remaining shareholders face uncertainty regarding the completion of the business combination and the company's going concern status.
• **Sponsor**: Continues to provide financial support through loans and extension payments, demonstrating commitment but also increasing its exposure. Benefits from the conversion of its promissory note into preferred stock at a 200% stated value upon merger completion.
• **Cyabra Strategy Ltd.**: The target company benefits from the ongoing efforts to complete the merger, the increased Base Purchase Price, and the financial advisory services secured. However, the delays and high redemptions could introduce uncertainty into the transaction.
• **Underwriters (LifeSci Capital LLC and Ladenburg Thalmann & Co. Inc.)**: LifeSci waived its advisory fee from Trailblazer but secured new advisory agreements with Cyabra, indicating a shift in their compensation structure and continued involvement with the combined entity. Underwriters will receive PubCo Shares for deferred underwriting commissions instead of cash.
• **Creditors**: The company's going concern uncertainty and low cash balance could pose risks to creditors if the business combination fails and the company liquidates. The Sponsor's agreement to indemnify the Trust Account provides some protection for public shareholders but not necessarily for other creditors.

Next Steps

• Complete the Business Combination with Cyabra Strategy Ltd. by March 30, 2026 (if fully extended).
• Address the identified material weakness in internal controls over financial reporting.
• Secure the PIPE Investment to support the Business Combination.
• List the combined entity, Cyabra, Inc., on The Nasdaq Stock Market, LLC.
• Continue to manage liquidity and potentially seek additional financing from the Sponsor or other parties.

Key Dates

Recommendation

The filing reveals a company in a precarious financial position, marked by a substantial net loss, critically low cash reserves, and a worsening stockholders' deficit. The "going concern" warning from management, coupled with repeated extensions of the business combination deadline and significant shareholder redemptions, signals high operational and financial risk. While the increase in the target's purchase price and the waiver of some advisory fees offer minor positives, they are overshadowed by the fundamental uncertainties and the identified material weakness in internal controls. The conversion of the Sponsor's promissory note into preferred stock at a 200% stated value upon merger completion, while beneficial to the Sponsor, could be dilutive or disadvantageous to other shareholders. Given the severe liquidity issues, the high probability of further redemptions, and the overall uncertainty surrounding the completion and success of the business combination, a seasoned investor would likely recommend selling to mitigate exposure to a potentially distressed asset.

Keywords

SPAC, Trailblazer Merger Corporation I, Cyabra Strategy Ltd., Business Combination, Merger Agreement, 10-Q, Financial Report, Going Concern, Shareholder Redemptions, Promissory Note, PIPE Investment, Nasdaq Listing, Corporate Governance, Risk Factors, SEC Filing